The present invention relates to a novel class of (R)-4-(heteroaryl)phenylpropionicderivatives of formula (I), useful in the inhibition of the chemotactic activationinduced by the fraction C5a of complement. Said compounds are useful in the treatmentof pathologies depending on the chemotactic activation of neutrophils and monocytesinduced by the fraction C5a of the complement. In particular, the compounds ofthe invention are useful in the treatment of autoimmune hemolytic anemia (AIHA),psoriasis, bullous pemphigoid, rheumatoid arthritis, ulcerative colitis,acute respiratory distress syndrome, idiopathic fibrosis, glomerulonephritisand in the prevention and treatment of injury caused by ischemia and reperfusion.
